Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | NSD2 | O96028 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29778809 | 0.73 | GRK6 (1.00) | GRK6MAPTKDM4ENSD2LMNA | |
| SCHEMBL8112 | 0.73 | GRK6 (1.00) | GRK6MAPTKDM4ENSD2LMNA | |
| Hydrochloric Acid SCHEMBL11423019 | 0.72 | GRK6 (0.96) | GRK6MAPTKDM4ENSD2LMNA | |
| Bromide SCHEMBL31741343 | 0.72 | GRK6 (0.96) | GRK6MAPTKDM4ENSD2HPGD | |
| SCHEMBL28021256 | 0.70 | GRK6 (0.56) | GRK6MAPTKDM4EKMT2AGAA | |
| SCHEMBL28021512 | 0.70 | GRK6 (0.56) | GRK6 | |
| Formaldehyde SCHEMBL27694578 | 0.69 | GRK6 (0.89) | GRK6MAPTKDM4ENSD2LMNA | |
| SCHEMBL27746989 | 0.67 | GRK6 (0.75) | GRK6MAPTKDM4ENSD2LMNA | |
| SCHEMBL8341033 | 0.67 | GRK6 (0.56) | GRK6 | |
| SCHEMBL28021161 | 0.67 | GRK6 (0.66) | GRK6MAPTKDM4ENSD2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009003952-A2 | COLUMN AND METHOD FOR PREPARING A BIOLOGICAL SAMPLE FOR PROTEIN PROFILING | PRONOTA N.V. (BE) | 2009-01-08 | — | — | WO | claimed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | UNIVERSITY OF DURHAM | 2023-12-05 | — | — | US | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| WO-2023161296-A1 | CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN | ADC THERAPEUTICS SA (CH) | 2023-08-31 | — | — | WO | disclosed |
| EP-4227304-A2 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| EP-3166640-B1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-06-14 | — | — | EP | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030225083-A1 | Antidiabetic agents | FAKHOURY STEPHEN A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY, LLC | 2003-11-27 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084535-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082276-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | GRK6 1224/4885MAPT 4698/4885KDM4E 1064/4885 |
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | RARA, RARB, RXRA | GRK6 2742/4885MAPT 4716/4885KDM4E 3685/4885 |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | GPR119, GCKR, GLP1R | GRK6 377/4885MAPT 4708/4885KDM4E 853/4885 |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | GRK6 4526/4885MAPT 991/4885KDM4E 2186/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | GRK6 2596/4885MAPT 4609/4885KDM4E 3710/4885 |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | GRK6 414/4885MAPT 4400/4885KDM4E 3250/4885 |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | GRK6 563/4885MAPT 4792/4885KDM4E 2934/4885 |
| US-20030225083-A1 | Antidiabetic agents | GPR119, IAPP, SLC5A1 | GRK6 1465/4885MAPT 4486/4885KDM4E 2111/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | GRK6 4526/4885MAPT 991/4885KDM4E 2186/4885 |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | ERBB2, EGFR, TP53 | GRK6 276/4885MAPT 555/4885KDM4E 2202/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | GRK6 1387/4885MAPT 140/4885KDM4E 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.